Key points are not available for this paper at this time.
mutation from that in the CLL leukemia cells. Collectively, these results provide insights into clonal evolution underlying ibrutinib relapse and prompt further investigation on genomic abnormalities that have clinical application potential.
Kadri et al. (Tue,) studied this question.